Last reviewed · How we verify

NCT05049421

The SWEDEGRAFT Right-Heart-Substudy

Completed Last updated 8 August 2023
What this trial tests

trial testing Echocardiography in Coronary Artery Bypass Surgery in 207 participants. Completed in 31 October 2022.

Timeline
10 August 2021
Primary endpoint
31 October 2022
31 October 2022

Quick facts

Lead sponsorAarhus University Hospital Skejby
StatusCompleted
Study typeOBSERVATIONAL
Enrollment207
Start date10 August 2021
Primary completion31 October 2022
Estimated completion31 October 2022
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Aarhus University Hospital Skejby

Who can join

Under 80, any sex, with Coronary Artery Bypass Surgery or Right-Sided Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BACKGROUND Right ventricular dysfunction is a common echocardiographic finding after cardiac surgery. Pericardial disruption has been suggested as the most probable cause as the phenomenon occurs within minutes after pericardial incision. The investigators suspect that validated two-dimensional echocardiographic measures for right ventricular function might not reflect the altered RV contraction pattern including paradoxical interventricular septal motion and reduced long-axis function following open cardiac surgery. The present study aims to determine the prevalence and scale of right ventricular dysfunction two years after CABG by applying the latest available two- and three-dimensional echocardiographic technology in right ventricular evaluation. In addition, the investigators investigate the impact of right ventricular dysfunction on functional outcome. METHODS The Right-Heart-Study is an observational substudy of the SWEDEGRAFT trial at Aarhus University Hospital in Denmark. SWEDEGRAFT is a nordic, multicenter, prospective, randomized, register-based, clinical trial (ClinicalTrials.gov Identifier: NCT03501303; Ragnarsson 2020). Patients for the current Right-Heart-Substudy will be recruited amongst the 269 patients included in the SWEDEGRAFT trial at Aarhus University Hospital from 10 September 2018 to 25 May 2020. Patients are enrolled at the time of SWEDEGRAFT follow-up with cardiac-CT (approximately 30 months after CABG). After written informed consent, we perform additional full 2D and 3D echocardiography with special focus on RV function, collect patient-reported data on functional outcome, and measure brain natriuretic peptide and hemoglobin levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Echocardiography

Trials testing the same drug.

Other recruiting trials for Coronary Artery Bypass Surgery

Currently open trials in the same condition.

Other Aarhus University Hospital Skejby trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05049421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing